Corey, Kathleen E.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 850

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 674

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 497

Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis

Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 413

Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis

Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 266

Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease

Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 180

Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies

Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., et al. (2018) · Hepatology

Metabolism, Diabetes, and CancerHepatocellular Carcinoma Treatment and Prognosis

Cited by 160

Machine learning enables new insights into genetic contributions to liver fat accumulation

Haas, M. E., Pirruccello, J. P., Friedman, S. N., Wang, M., Emdin, C. A., Ajmera, V. H., Simon, T. G., Homburger, J. R., Guo, X., Budoff, M., et al. (2021) · Cell Genomics

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 118

American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease

Stine, J. G., Long, M. T., Corey, K. E., Sallis, R. E., Allen, A. M., Armstrong, M. J., Conroy, D. E., Cuthbertson, D. J., Duarte-Rojo, A., Hallsworth, K., et al. (2023) · Hepatology Communications

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 89

Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis

Samur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 89

ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD

Corey, K. E., Pitts, R., Lai, M., Loureiro, J., Masia, R., Osganian, S. A., Gustafson, J. L., Hutter, M. M., Gee, D. W., Meireles, O. R., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis

Corey, K. E., Klebanoff, M. J., Tramontano, A. C., Chung, R. T., & Hur, C. (2016) · Digestive Diseases and Sciences

Liver Disease Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 84

The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity

Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020) · Obesity Science & Practice

Pharmacology and Obesity TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 61

Physical activity compared to adiposity and risk of liver-related mortality: results from two prospective, nationwide cohorts

Simon, T. G., Kim, M. N., Luo, X., Yang, W., Ma, Y., Chong, D. Q., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 57

Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: evidence from mediation analysis

Kim, M. N., Lo, C.-H., Corey, K. E., Luo, X., Long, L., Zhang, X., Chan, A. T., & Simon, T. G. (2022) · Clinical Nutrition

Liver Disease Diagnosis and TreatmentNutritional Studies and Diet

Cited by 51

Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis

Martin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 45

Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study

Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases

HIV-related health complications and treatmentsNutrition and Health in Aging

Cited by 44

WSTF nuclear autophagy regulates chronic but not acute inflammation

Wang, Y., Eapen, V. V., Liang, Y., Kournoutis, A., Sherman, M. S., Xu, Y., Onorati, A., Li, X., Zhou, X., Corey, K. E., et al. (2025) · Nature

Autophagy in Disease and TherapyGenomics and Chromatin Dynamics

Cited by 30

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 23